(Q38747100)

6 September 2017

title

Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents (English)

1 reference

6 September 2017

0 references

Per Soelberg Sørensen

series ordinal

2

object named as

Per Soelberg Sørensen

1 reference

6 September 2017

1

Morten Blinkenberg

1 reference

6 September 2017

publication date

11 March 2017

1 reference

6 September 2017

1 reference

6 September 2017

volume

31

1 reference

6 September 2017

issue

5

1 reference

6 September 2017

page(s)

357-371

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-017-0414-3

6 September 2017

exact match

0 references

cites work

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

New management algorithms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab: the advantages and challenges of a novel therapy in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Immune competence after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

The biology of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

In vivo maintenance of human regulatory T cells during CD25 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

A function for interleukin 2 in Foxp3-expressing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Control of regulatory T cell development by the transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

The evidence for a role of B cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Follicular helper CD4 T cells (TFH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

The good, the bad and the ugly - TFH cells in human health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Rituximab in paediatric onset multiple sclerosis: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Treatment of multiple sclerosis with anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Safety concerns and risk management of multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-017-0414-3

CD4+CD25high regulatory cells in human peripheral blood

21 January 2018

1 reference

12 December 2020

Characterization of a human B lymphocyte-specific antigen.

1 reference

12 December 2020

Biology of the interleukin-2 receptor

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events

1 reference

12 December 2020

Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab

1 reference

12 December 2020

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

1 reference

12 December 2020

Hy's law: predicting serious hepatotoxicity

1 reference

12 December 2020

The role of B cells and autoantibodies in multiple sclerosis

1 reference

12 December 2020

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

1 reference

12 December 2020

Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers

1 reference

12 December 2020

Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis

1 reference

12 December 2020

B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application

1 reference

12 December 2020

10.1007/S40263-017-0414-3

Identifiers

DOI

1 reference

6 September 2017

1 reference